KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Revenue (2019 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Revenue for 7 consecutive years, with -$1.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue fell 101.75% year-over-year to -$1.0 million, compared with a TTM value of $204.9 million through Dec 2025, down 12.86%, and an annual FY2025 reading of -$4.3 million, down 101.84% over the prior year.
  • Revenue was -$1.0 million for Q4 2025 at Aurinia Pharmaceuticals, down from $73.5 million in the prior quarter.
  • Across five years, Revenue topped out at $73.5 million in Q3 2025 and bottomed at -$1.0 million in Q4 2025.
  • Average Revenue over 5 years is $39.8 million, with a median of $43.3 million recorded in 2023.
  • The sharpest move saw Revenue surged 50475.86% in 2021, then crashed 101.75% in 2025.
  • Year by year, Revenue stood at $23.4 million in 2021, then grew by 21.5% to $28.4 million in 2022, then surged by 58.59% to $45.1 million in 2023, then surged by 32.76% to $59.9 million in 2024, then plummeted by 101.75% to -$1.0 million in 2025.
  • Business Quant data shows Revenue for AUPH at -$1.0 million in Q4 2025, $73.5 million in Q3 2025, and $70.0 million in Q2 2025.